Evidence map›Paper›PMID 40796898›Full record

ArticleBreast cancer research : BCR2025

Exosome-delivered METTL14 drives hypoxia-induced proliferation, metastasis, and glycolysis of breast cancer cells through regulating TRIM16-mediated FGF7 ubiquitination.

Bo Huang, Yichao Zhang, Zhanjun Chen, Yuanyuan Yuan, Jianshan Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bo HuangDepartment of Thyroid and Breast Surgery, The Second Affiliated Hospital of Shenzhen University, No.118, Longjing Second Road, Xin'an Street, Baoan District, Shenzhen, Guangdong, 518101, China.
Yichao ZhangDepartment of Thyroid and Breast Surgery, The Second Affiliated Hospital of Shenzhen University, No.118, Longjing Second Road, Xin'an Street, Baoan District, Shenzhen, Guangdong, 518101, China.
Zhanjun ChenDepartment of Thyroid and Breast Surgery, The Second Affiliated Hospital of Shenzhen University, No.118, Longjing Second Road, Xin'an Street, Baoan District, Shenzhen, Guangdong, 518101, China.
Yuanyuan YuanDepartment of Thyroid and Breast Surgery, The Second Affiliated Hospital of Shenzhen University, No.118, Longjing Second Road, Xin'an Street, Baoan District, Shenzhen, Guangdong, 518101, China.
Jianshan LinDepartment of Thyroid and Breast Surgery, The Second Affiliated Hospital of Shenzhen University, No.118, Longjing Second Road, Xin'an Street, Baoan District, Shenzhen, Guangdong, 518101, China. bayyjrwk@163.com.

Funding

Shenzhen Baoan district Medical Association Medical research project BAYXH2024002
6 · The paper itself

Abstract

backgroundTriple-negative breast cancer (TNBC) is an aggressive type of breast cancer and has a poor prognosis. Previous studies have indicated that Fibroblast Growth Factor 7 (FGF7) plays a vital role in the development and progression of breast cancer. However, the role and molecular mechanisms of FGF7 in TNBC remain largely unclear under hypoxia.

methodsFGF7 and Methyltransferase-like 14 (METTL14) levels were detected by real-time quantitative polymerase chain reaction (RT-qPCR). FGF7, tripartite motif-containing protein 16 (TRIM16), METTL14, METTL3, YTHDF1, WTAP, FTO, CD63, CD81, and TSG101 protein levels were examined by western blot. Cell viability, proliferation, invasion, and migration were determined using MTT, EdU, transwell, and wound healing assays. Glucose consumption, lactate production, and ATP levels were assessed using relevant kits. After STRING database analysis, the interaction between TRIM16 and FGF7 was verified using a Co-immunoprecipitation (CoIP) assay. Interaction between METTL14 and TRIM16 was validated using methylated RNA immunoprecipitation (MeRIP), RIP, and dual-luciferase reporter assays. The biological role of hypoxia-induced exosomal METTL14 on breast cancer tumor growth was assessed using the xenograft tumor model in vivo.

resultsFGF7 was highly expressed in TNBC patients and cell lines. Moreover, FGF7 expression was increased in the hypoxia group compared with the normoxia group. Functionally, FGF7 knockdown suppressed hypoxia-induced TNBC cell proliferation, metastasis, and glycolysis. Mechanistically, TRIM16 triggered the ubiquitination of FGF7 and promoted its degradation. METTL14 enhanced TRIM16 mRNA stability and expression by m6A methylation. Hypoxia-induced exosomal METTL14 knockdown repressed tumor growth in vivo.

conclusionHypoxia-induced exosomal METTL14 supports the proliferation, metastasis, and glycolysis of TNBC cells through regulating TRIM16-mediated FGF7 ubiquitination, providing a promising therapeutic target for TNBC treatment.

Indexed as

ExosomesFibroblast Growth Factor 7MethyltransferasesTranscription FactorsTripartite Motif ProteinsTriple Negative Breast NeoplasmsUbiquitin-Protein LigasesAnimalsCell HypoxiaCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticGlycolysisHumansFGF7 protein, humanFibroblast Growth Factor 7MethyltransferasesMETTL14 protein, humanTranscription FactorsTripartite Motif ProteinsUbiquitin-Protein LigasesFGF7HypoxiaMETTL14ProliferationTNBCTRIM16

Identifiers

PMID40796898
PMCPMC12345010

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.